Replimune Secures $200 Million In Non-Dilutive Debt Financing From Hercules Capital, Inc.
10/07/22, 12:06 PM
Location
woburnMoney raised
$200 million
Industry
biotechnology
health care
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that it has obtained a $200 million non-dilutive term loan facility from Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets. This non-dilutive capital extends cash runway into 2025 ahead of key catalysts from the Company’s registration-directed CERPASS and IGNYTE trials in cutaneous squamous cell carcinoma (CSCC) and anti-PD1 failed melanoma inclusive of the costs of funding commercial infrastructure and the running of a confirmatory study to support a potential BLA filing in anti-PD1 failed melanoma.
Company Info
Location
woburn, massachusetts, united states
Additional Info
Replimune is working to advance the science of oncolytic immunotherapy to improve on existing therapies and help treat more patients with a variety of tumor types. Oncolytic immunotherapy uses viruses that have been modified to selectively replicate in and kill tumors.
Replimunes' goal is to develop powerful therapies to overcome cancer.